Developing a new adjuvant to enhance vaccine effectiveness against bacterial and fungal infections
Official title: DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM
Funded at University of Montana · NIH-11127338 · Data updated 2026-11-12
This study is testing a new helper ingredient called UM-1098 that aims to make vaccines work better against infections like tuberculosis and certain fungal diseases, and if you're interested, you might have the chance to join the trials to see how well it works with current vaccines.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Montana NIH-funded |
| Lab location | 1 site (Missoula, United States) |
| Project start | September 30, 2023 |
| Project end | September 29, 2028 |
| Funding year | 2024 |
| Award (this year) | $5,504,851 |
| NIH project number | 75N93023C00047-P00001-9999-1 |
| Project ID | NIH-11127338 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would include individuals at risk for infections caused by the targeted pathogens, such as those with weakened immune systems or chronic respiratory conditions.
✕Less likely to help
Patients who are not at risk for the targeted infections or those who have already received effective vaccinations may not benefit from this research.
What this research studies
This research focuses on creating and testing a new synthetic adjuvant, UM-1098, designed to boost the immune response against various bacterial and fungal pathogens. The approach involves using a novel nanoparticle delivery system to enhance the effectiveness of vaccines, particularly for diseases like tuberculosis and infections caused by Bordetella pertussis and Candida albicans. The research will evaluate the safety and efficacy of this adjuvant in human clinical trials, following promising results in animal models. Patients may have the opportunity to participate in trials that assess how well this new adjuvant works in combination with existing vaccines.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide better protection against serious bacterial and fungal infections.
How similar studies have gone: Previous research has shown success with similar adjuvant approaches, indicating potential for this novel adjuvant to improve vaccine responses.
Where this research is happening
-
University of Montana
Missoula, United States Active
Researchers
- Principal investigator: Evans, Jay — University of Montana
- Study coordinator: Evans, Jay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.